Director of Provider Services MATClinics Berlin, Maryland
Presentation Summary: Explore best practices for transitioning between methadone, buprenorphine, and naltrexone in opioid use disorder treatment, emphasizing long-acting injectables (LAIs). LAI improves adherence and reduces withdrawal risks, promotes treatment engagement, and enhances patient outcomes. A case study will highlight a novel approach to the transition process using LAI.
Learning Objectives:
At the completion of this activity, participants will:
Describe current evidenced based practices for transitioning between methadone, buprenorphine, and naltrexone.
Analyze a case study illustrating a novel approach to transitioning between buprenorphine and naltrexone, identifying key clinical challenges and solutions.
Evaluate the feasibility of using long acting injectable medications as part of a comprehensive transition strategy.
